| Name | Ramucirumab |
|---|
| Description | Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors[1]. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D[2]. |
|---|---|
| Related Catalog | |
| Target |
VEGFR-2 |
| References |
| Molecular Formula | C285H434N74O88S2 |
|---|---|
| Molecular Weight | 6369.07 |